Comparable complement-fixing antigens of type 1 and type 2 herpes simplex virus were produced by extraction of infected African green monkey cells with 0.85%o NaCl which was buffered at pH 9.0 with 0.05 M glycine-NaOH. The optimal antigen dilutions were higher in titrations against hyperimmune animal sera than in titrations against human sera. Complement-fixing antibody to type 2 herpes antigen was detected in 5 of 17 sera from healthy humans. The pellet from this centrifugation was resuspended in sufficient 0.85% NaCl, buffered at pH 9.0 with 0.05 M glycine-NaOH, to effect a 20-fold concentration of the original material; this suspension was then treated sonically for 10 min in a Ratyheon sonic oscillator. The sonically treated material was used as CF antigen without further treatment. Uninfected cell cultures treated the same way were used as control antigens. CF tests were performed with these antigens by the LBCF method (1). This method defines the optimal antigen dilution as that which gives the greatest amount of complement fixation with specific antiserum without being anticomplementary. Table 1 presents data derived from titrations of VR no. 3 and MS CF antigens for determination of optimal antigen dilutions. The sera included in this table are hyperimmune rabbit anti-type 1 and anti-type 2 HSV sera and human sera typed as HSV type 1 or type 2 by the micro indirect hemagglutination (2) and quantal neutralization (8) methods. The data in Table 1 show that the optimal dilution of both herpes types was 1:32 when the two antigens were titrated against hyperimmune rabbit anti-HSV serum. However, the optimal dilution was 1:16 when the VR no. 3 antigen was titrated against a human anti-type 1 serum, and the MS antigen was titrated only 1:4 against its homologous human antiserum. It is therefore suggested that the appropriate antigen dilutions for HSV type 1 and type 2 CF antigens be determined for the particular system in which they are to be used. We have consistently noted that the optimal dilution of antigen will be higher when it is tested against a hyperimmune animal serum than against a human serum. 
The complement fixation (CF) test has been used for a number of years as a routine test for the serological diagnosis of herpetic infection. In view of the more recent interest in the sero-epidemiological potential of evaluating humoral antibody responses in humans to type 1 and type 2 herpes simplex virus (HSV) (6) , it has become pertinent to define the value and limitations of this test in differentiating herpes type-specific antibody in human sera.
The unavailability of an adequate CF antigen has limited serological studies of type The pellet from this centrifugation was resuspended in sufficient 0.85% NaCl, buffered at pH 9.0 with 0.05 M glycine-NaOH, to effect a 20-fold concentration of the original material; this suspension was then treated sonically for 10 min in a Ratyheon sonic oscillator. The sonically treated material was used as CF antigen without further treatment. Uninfected cell cultures treated the same way were used as control antigens. CF tests were performed with these antigens by the LBCF method (1). This method defines the optimal antigen dilution as that which gives the greatest amount of complement fixation with specific antiserum without being anticomplementary. Table 1 show that the optimal dilution of both herpes types was 1:32 when the two antigens were titrated against hyperimmune rabbit anti-HSV serum. However, the optimal dilution was 1:16 when the VR no. 3 antigen was titrated against a human anti-type 1 serum, and the MS antigen was titrated only 1:4 against its homologous human antiserum. It is therefore suggested that the appropriate antigen dilutions for HSV type 1 and type 2 CF antigens be determined for the particular system in which they are to be used. We have consistently noted that the optimal dilution of antigen will be higher when it is tested against a hyperimmune animal serum than against a human serum. Table 2 
